Without a doubt, the breast cancer community has witnessed in the last years the most important advancements in the medical treatment for all breast cancer subtypes since decades. Such advancements embrace the whole spectrum of breast cancer care and include the introduction of new drugs, the complete redefinition of treatment decision-trees, and the introduction of new diagnostic tools. All these changes are fueled by new acquisitions coming from both fundamental, translational and clinical research at an unprecedented speed and we can foresee that, at this pace, even more profound changes could come in the following years. In this evolving scenario, it is essential to keep a critical eye on the knowledge generated by the scientific literature, to carefully put new data in the context of the established knowledge, and to look at this changing landscape trying to anticipate potential future avenues. It is also very important that, as these changes happen, we are fully aware of the many implications that they may carry, starting from the practical aspects of introducing these novelties in our daily routine and including those aspects related to the communication with the patients and their caregivers. As members of a community dedicated to breast cancer care, we also have the imperative of understanding what is the current role of all the different players concurring to the development of new breast cancer therapies. In particular, it is urgent to reflect on the current status of independent research worldwide and on the role that this is going to have in the near future.